Immuno-Oncology Drugs Market 2027 by Types, Application, Technology, Opportunities, End Users and Regions | The Insight Partners

Immuno-Oncology Drugs Market to 2027 - Global Analysis and Forecasts by Drug Type (Immune Checkpoint Inhibitors, Monoclonal Antibodies, Cytokine Based Immunotherapy, Cancer Vaccines, CAR-T Cell Therapy,); Therapeutic Application (Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Prostate Cancer, Bladder Cancer, Others); End User (Hospitals, Clinics, Ambulatory Surgical Centers)

Report Code: TIPRE00004055 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
MARKET INTRODUCTION
Oncology medications are flourishing business for the pharmaceutical industry. Almost the major market players in this field are either manufacturing oncology drugs or have oncology medications in their pipeline as potential medications to sell in the coming years. Cancer affects millions of people across the globe. Robust research and development activities are going on to develop new drug entity in order to treat cancer. Based on their function of these drugs, they are further classified into subtypes such as radiolabeled antibodies, chemo labeled antibodies and bispecific monoclonal antibodies.

MARKET DYNAMICS
The immuno-oncology drugs market is anticipated to grow in the forecast, owing to the factors such as increasing prevalence of cancer, growing immune-oncology therapies, technological advancement in the field of drug discovery and increasing awareness amongst the patients. However, high cost of the treatment and risk associated with the treatment hampers the growth of the market.

MARKET SCOPE
The "Global Immuno-oncology Drugs Market Analysis to 2027" is a specialized and in-depth study of the pharmaceuticals industry with a special focus on the global market trend analysis. The report aims to provide an overview of immuno-oncology drugs market with detailed market segmentation by drug type, therapeutic application, end user and geography. The global immuno-oncology drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading immuno-oncology drugs market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION
The global immuno-oncology drugs market is segmented on the basis of drug type, therapeutic application, end user. Based on drug type, the market is segmented as immune checkpoint inhibitors, monoclonal antibodies, cytokine based immunotherapy, cancer vaccines, Car-T cell therapy. On the basis of therapeutic application, the global immuno-oncology drugs market is segmented into melanoma, lung cancer, blood cancer, renal cell carcinoma, prostate cancer, bladder cancer, others. The end user segment is further segmented into hospitals, clinics, ambulatory surgical centers.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Iimmuno-oncology drugs market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Immuno-oncology drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Immuno-oncology drugs market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the immuno-oncology drugs market in these regions.

MARKET PLAYERS
The reports cover key developments in the immuno-oncology drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from immuno-oncology drugs market are anticipated to lucrative growth opportunities in the future with the rising demand for immuno-oncology drugs market in the global market. Below mentioned is the list of few companies engaged in the immuno-oncology drugs market.

The report also includes the profiles of key immuno-oncology drugs market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
  • Amgen, Inc.
  • Astrazeneca Plc
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Eli lilly and Company
  • Sanofi
  • F. Hoffmann-La Roche
  • Novartis AG
  • Abbvie, Inc.
  • Pfizer Inc.
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Immuno-Oncology Drugs Market - By Drug Type
1.3.2 Immuno-Oncology Drugs Market - By Therapeutic Application
1.3.3 Immuno-Oncology Drugs Market - By End User
1.3.4 Immuno-Oncology Drugs Market - By Region
1.3.4.1 By Country
2. KEY TAKEWAYS
3. RESEARCH METHODOLOGY
4. IMMUNO-ONCOLOGY DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. IMMUNO-ONCOLOGY DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. IMMUNO-ONCOLOGY DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. IMMUNO-ONCOLOGY DRUGS - GLOBAL MARKET OVERVIEW
6.2. IMMUNO-ONCOLOGY DRUGS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE

7. IMMUNO-ONCOLOGY DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - DRUG TYPE
7.1. OVERVIEW
7.2. DRUG TYPE MARKET FORECASTS AND ANALYSIS
7.3. IMMUNE CHECKPOINT INHIBITORS
7.3.1. Overview
7.3.2. Immune Checkpoint Inhibitors Market Forecast and Analysis
7.4. MONOCLONAL ANTIBODIES
7.4.1. Overview
7.4.2. Monoclonal Antibodies Market Forecast and Analysis
7.5. CYTOKINE BASED IMMUNOTHERAPY
7.5.1. Overview
7.5.2. Cytokine Based Immunotherapy Market Forecast and Analysis
7.6. CANCER VACCINES
7.6.1. Overview
7.6.2. Cancer Vaccines Market Forecast and Analysis
7.7. CAR-T CELL THERAPY
7.7.1. Overview
7.7.2. CAR-T Cell Therapy Market Forecast and Analysis
8. IMMUNO-ONCOLOGY DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - THERAPEUTIC APPLICATION
8.1. OVERVIEW
8.2. THERAPEUTIC APPLICATION MARKET FORECASTS AND ANALYSIS
8.3. MELANOMA
8.3.1. Overview
8.3.2. Melanoma Market Forecast and Analysis
8.4. LUNG CANCER
8.4.1. Overview
8.4.2. Lung Cancer Market Forecast and Analysis
8.5. BLOOD CANCER
8.5.1. Overview
8.5.2. Blood Cancer Market Forecast and Analysis
8.6. RENAL CELL CARCINOMA
8.6.1. Overview
8.6.2. Renal Cell Carcinoma Market Forecast and Analysis
8.7. PROSTATE CANCER
8.7.1. Overview
8.7.2. Prostate Cancer Market Forecast and Analysis
8.8. BLADDER CANCER
8.8.1. Overview
8.8.2. Bladder Cancer Market Forecast and Analysis
8.9. OTHERS
8.9.1. Overview
8.9.2. Others Market Forecast and Analysis
9. IMMUNO-ONCOLOGY DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - END USER
9.1. OVERVIEW
9.2. END USER MARKET FORECASTS AND ANALYSIS
9.3. HOSPITALS
9.3.1. Overview
9.3.2. Hospitals Market Forecast and Analysis
9.4. CLINICS
9.4.1. Overview
9.4.2. Clinics Market Forecast and Analysis
9.5. AMBULATORY SURGICAL CENTERS
9.5.1. Overview
9.5.2. Ambulatory Surgical Centers Market Forecast and Analysis
10. IMMUNO-ONCOLOGY DRUGS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Immuno-Oncology Drugs Market Overview
10.1.2 North America Immuno-Oncology Drugs Market Forecasts and Analysis
10.1.3 North America Immuno-Oncology Drugs Market Forecasts and Analysis - By Drug Type
10.1.4 North America Immuno-Oncology Drugs Market Forecasts and Analysis - By Therapeutic Application
10.1.5 North America Immuno-Oncology Drugs Market Forecasts and Analysis - By End User
10.1.6 North America Immuno-Oncology Drugs Market Forecasts and Analysis - By Countries
10.1.6.1 United States Immuno-Oncology Drugs Market
10.1.6.1.1 United States Immuno-Oncology Drugs Market by Drug Type
10.1.6.1.2 United States Immuno-Oncology Drugs Market by Therapeutic Application
10.1.6.1.3 United States Immuno-Oncology Drugs Market by End User
10.1.6.2 Canada Immuno-Oncology Drugs Market
10.1.6.2.1 Canada Immuno-Oncology Drugs Market by Drug Type
10.1.6.2.2 Canada Immuno-Oncology Drugs Market by Therapeutic Application
10.1.6.2.3 Canada Immuno-Oncology Drugs Market by End User
10.1.6.3 Mexico Immuno-Oncology Drugs Market
10.1.6.3.1 Mexico Immuno-Oncology Drugs Market by Drug Type
10.1.6.3.2 Mexico Immuno-Oncology Drugs Market by Therapeutic Application
10.1.6.3.3 Mexico Immuno-Oncology Drugs Market by End User
10.2. EUROPE
10.2.1 Europe Immuno-Oncology Drugs Market Overview
10.2.2 Europe Immuno-Oncology Drugs Market Forecasts and Analysis
10.2.3 Europe Immuno-Oncology Drugs Market Forecasts and Analysis - By Drug Type
10.2.4 Europe Immuno-Oncology Drugs Market Forecasts and Analysis - By Therapeutic Application
10.2.5 Europe Immuno-Oncology Drugs Market Forecasts and Analysis - By End User
10.2.6 Europe Immuno-Oncology Drugs Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Immuno-Oncology Drugs Market
10.2.6.1.1 Germany Immuno-Oncology Drugs Market by Drug Type
10.2.6.1.2 Germany Immuno-Oncology Drugs Market by Therapeutic Application
10.2.6.1.3 Germany Immuno-Oncology Drugs Market by End User
10.2.6.2 France Immuno-Oncology Drugs Market
10.2.6.2.1 France Immuno-Oncology Drugs Market by Drug Type
10.2.6.2.2 France Immuno-Oncology Drugs Market by Therapeutic Application
10.2.6.2.3 France Immuno-Oncology Drugs Market by End User
10.2.6.3 Italy Immuno-Oncology Drugs Market
10.2.6.3.1 Italy Immuno-Oncology Drugs Market by Drug Type
10.2.6.3.2 Italy Immuno-Oncology Drugs Market by Therapeutic Application
10.2.6.3.3 Italy Immuno-Oncology Drugs Market by End User
10.2.6.4 Spain Immuno-Oncology Drugs Market
10.2.6.4.1 Spain Immuno-Oncology Drugs Market by Drug Type
10.2.6.4.2 Spain Immuno-Oncology Drugs Market by Therapeutic Application
10.2.6.4.3 Spain Immuno-Oncology Drugs Market by End User
10.2.6.5 United Kingdom Immuno-Oncology Drugs Market
10.2.6.5.1 United Kingdom Immuno-Oncology Drugs Market by Drug Type
10.2.6.5.2 United Kingdom Immuno-Oncology Drugs Market by Therapeutic Application
10.2.6.5.3 United Kingdom Immuno-Oncology Drugs Market by End User
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Immuno-Oncology Drugs Market Overview
10.3.2 Asia-Pacific Immuno-Oncology Drugs Market Forecasts and Analysis
10.3.3 Asia-Pacific Immuno-Oncology Drugs Market Forecasts and Analysis - By Drug Type
10.3.4 Asia-Pacific Immuno-Oncology Drugs Market Forecasts and Analysis - By Therapeutic Application
10.3.5 Asia-Pacific Immuno-Oncology Drugs Market Forecasts and Analysis - By End User
10.3.6 Asia-Pacific Immuno-Oncology Drugs Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Immuno-Oncology Drugs Market
10.3.6.1.1 Australia Immuno-Oncology Drugs Market by Drug Type
10.3.6.1.2 Australia Immuno-Oncology Drugs Market by Therapeutic Application
10.3.6.1.3 Australia Immuno-Oncology Drugs Market by End User
10.3.6.2 China Immuno-Oncology Drugs Market
10.3.6.2.1 China Immuno-Oncology Drugs Market by Drug Type
10.3.6.2.2 China Immuno-Oncology Drugs Market by Therapeutic Application
10.3.6.2.3 China Immuno-Oncology Drugs Market by End User
10.3.6.3 India Immuno-Oncology Drugs Market
10.3.6.3.1 India Immuno-Oncology Drugs Market by Drug Type
10.3.6.3.2 India Immuno-Oncology Drugs Market by Therapeutic Application
10.3.6.3.3 India Immuno-Oncology Drugs Market by End User
10.3.6.4 Japan Immuno-Oncology Drugs Market
10.3.6.4.1 Japan Immuno-Oncology Drugs Market by Drug Type
10.3.6.4.2 Japan Immuno-Oncology Drugs Market by Therapeutic Application
10.3.6.4.3 Japan Immuno-Oncology Drugs Market by End User
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Immuno-Oncology Drugs Market Overview
10.4.2 Middle East and Africa Immuno-Oncology Drugs Market Forecasts and Analysis
10.4.3 Middle East and Africa Immuno-Oncology Drugs Market Forecasts and Analysis - By Drug Type
10.4.4 Middle East and Africa Immuno-Oncology Drugs Market Forecasts and Analysis - By Therapeutic Application
10.4.5 Middle East and Africa Immuno-Oncology Drugs Market Forecasts and Analysis - By End User
10.4.6 Middle East and Africa Immuno-Oncology Drugs Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Immuno-Oncology Drugs Market
10.4.6.1.1 South Africa Immuno-Oncology Drugs Market by Drug Type
10.4.6.1.2 South Africa Immuno-Oncology Drugs Market by Therapeutic Application
10.4.6.1.3 South Africa Immuno-Oncology Drugs Market by End User
10.4.6.2 Saudi Arabia Immuno-Oncology Drugs Market
10.4.6.2.1 Saudi Arabia Immuno-Oncology Drugs Market by Drug Type
10.4.6.2.2 Saudi Arabia Immuno-Oncology Drugs Market by Therapeutic Application
10.4.6.2.3 Saudi Arabia Immuno-Oncology Drugs Market by End User
10.4.6.3 U.A.E Immuno-Oncology Drugs Market
10.4.6.3.1 U.A.E Immuno-Oncology Drugs Market by Drug Type
10.4.6.3.2 U.A.E Immuno-Oncology Drugs Market by Therapeutic Application
10.4.6.3.3 U.A.E Immuno-Oncology Drugs Market by End User
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Immuno-Oncology Drugs Market Overview
10.5.2 South and Central America Immuno-Oncology Drugs Market Forecasts and Analysis
10.5.3 South and Central America Immuno-Oncology Drugs Market Forecasts and Analysis - By Drug Type
10.5.4 South and Central America Immuno-Oncology Drugs Market Forecasts and Analysis - By Therapeutic Application
10.5.5 South and Central America Immuno-Oncology Drugs Market Forecasts and Analysis - By End User
10.5.6 South and Central America Immuno-Oncology Drugs Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Immuno-Oncology Drugs Market
10.5.6.1.1 Brazil Immuno-Oncology Drugs Market by Drug Type
10.5.6.1.2 Brazil Immuno-Oncology Drugs Market by Therapeutic Application
10.5.6.1.3 Brazil Immuno-Oncology Drugs Market by End User
10.5.6.2 Argentina Immuno-Oncology Drugs Market
10.5.6.2.1 Argentina Immuno-Oncology Drugs Market by Drug Type
10.5.6.2.2 Argentina Immuno-Oncology Drugs Market by Therapeutic Application
10.5.6.2.3 Argentina Immuno-Oncology Drugs Market by End User
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. IMMUNO-ONCOLOGY DRUGS MARKET, KEY COMPANY PROFILES
12.1. AMGEN, INC.
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. ASTRAZENECA PLC
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. BRISTOL-MYERS SQUIBB
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. CELGENE CORPORATION
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. ELI LILLY AND COMPANY
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. SANOFI
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. F. HOFFMANN-LA ROCHE
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. NOVARTIS AG
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. ABBVIE, INC.
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. PFIZER INC.
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

1. Amgen, Inc.
2. Astrazeneca Plc
3. Bristol-Myers Squibb
4. Celgene Corporation
5. Eli lilly and Company
6. Sanofi
7. F. Hoffmann-La Roche
8. Novartis AG
9. Abbvie, Inc.
10. Pfizer Inc.